Introduction
Thrombin is one of the most potent platelet agonists, acting via two protease-activated receptors (PARs), PAR1 and PAR4. The N-terminal exodomain of these receptors are cleaved off, and the unmasked newly exposed N-terminus serves as a tethered ligand docking intra-molecularly onto the receptor, thereby inducing signaling through its coupled G proteins [1, 2] . Although the evolutionary benefits of this seemingly redundant dual receptor configuration are unknown, emerging clinical and experimental evidence support the notion that the two PAR receptors have distinct but complementary roles in platelet biology. While platelets respond with a transient "spike" in the intracellular calcium concentration upon stimulation of PAR1, PAR4 stimulation gives rise to a much more prolonged calcium mobilization, supposedly due to different kinetics of receptor phosphorylation and internalization [2] . PAR1 is more sensitive to low concentrations of thrombin than PAR4 [1] and is more effective in rapidly mobilizing platelet haemostatic functions, such as the release of bioactive cargo stored in granules [3] . Maximal activation of PAR4 results in more fibrinogen bound to the platelet and a higher clot elasticity [4] . PAR1 has also been shown to be more susceptible to desensitization than PAR4 [5] .
The catalytic activity and specificity of thrombin is highly dependent on two intramolecular recognition sites located distant from the active site. These domains, designated fibrinogen recognition site and heparin binding site, or exosite I and II respectively, facilitate proteolysis by interacting with anionic surfaces on various substrates, and are the target of several physiologically important thrombomodulatory agents including antithrombin [6] . Exosite I is the binding epitope for fibrinogen, thrombomodulin, hirudin, and PAR1. Exosite II binds to heparin and potentially also to GPIb [7] [8] [9] [10] . Exosites I and II on thrombin may be blocked by the DNA-oligomers HD1 and HD22, respectively [11] . The binding of thrombin exosite I to PAR1 is mediated by a hirudin-like sequence immediately downstream of the tethered ligand domain. This sequence does not exist on PAR4. Instead, thrombin has been reported to have low affinity for the thrombin cleavage site of PAR4 [12] . Both PAR1 and PAR4 can cause platelet activation and aggregation single-handedly, but the activation of PAR4 by thrombin is accelerated by the presence of PAR1 [13] , suggesting a cofactor function for PAR1.
PAR1 is a typical G protein coupled receptor (GPCR), comprised of seven transmembrane helices that are connected by intracellular and extracellular loops, and are arranged around a central pocket [14] . Extracellular loop II (ECLII) is located between transmembrane helices 4 and 5. In PAR 1, ECLII is a binding site for the tethered ligand [15] but very little is known about the homologous region on PAR4.
Both PAR1 and PAR4 display a high concentration of anionic residues in ECL II, and the same is true for the N-terminal region of both receptors. Work by Nieman's group has shown that anionic residues in the N-terminal of PAR4 are important for its interaction with α-thrombin both in the presence and absence of PAR1 [16] . In a previous report, we presented evidence for a pivotal role for exosite II in PAR4-dependent activation of platelets by thrombin [17] . There are also reports stating that the exosite II residue W215 in thrombin is important as it affects thrombin activation of platelets via hydrophobic interactions [18] .
The location and features of thrombin's exosite II makes it difficult to study as it is composed by several amino acids arising from different chains, but it is known that the residues R93, R101, R233, K235, K236, and K240 are important for thrombin's interaction with heparin [10] and with GpIb. So, we can assume that amino acids of PAR4 that interact with exosite II would most likely be anionic ones, to facilitate electrostatic interactions. For this reason, in this work, we chose to study how specific electronegative amino acids within the N-terminal and ECLII of PAR4 contribute to PAR4 activation. To help investigate the mechanism, γ-thrombin, a non-physiological proteolytic product of α-thrombin which lacks exosite I was used as a tool. In addition, we designed short peptides that mimic the N-terminal and extracellular domains of PAR4 as candidates for the interaction with exosite II on thrombin. Our results indicate a role for ECLII in thrombin activation of PAR4 and as the binding partner for the newly formed N-terminal of PAR4 after cleavage by thrombin.
Materials and Methods
Chemicals All peptides were purchased as lyophilized powders. Except for PAR4-activating peptide (PAR4-AP, sequence AYPGKF) which was purchased from JPT Peptide Technologies GmbH (Berlin, Germany), all other peptides were purchased from GeneCust (Dudelange, Luxembourg) with a certified purity of 99.5 %. Stock peptide solutions were prepared at 10 mM concentrations in deionized water. Peptide properties are listed in Table 2 . α-thrombin was purchased from Sigma Aldrich (St Louis, MO, US) and dissolved to a stock solution of 200 U/mL, which is equivalent to 1360 nM. γ-thrombin (a thrombin variant lacking exosite I) was purchased from Coatech (Gothenburg, Sweden) and dissolved to make a stock concentration of 1 μM. γ -thrombin for binding assays were purchased as lyophilized powder with a certified purity higher than 99% from Enzyme Diagnostic Research (Swansea, UK). Apyrase from potato, grade VI, Ref A6535 was purchased from Sigma Aldrich. HEPES buffer (145 mM NaCl, 5 mM KCl, 1 mM MgSO4, 10 mM HEPES and 10 mM glucose, pH 7.4) and Krebs Ringer Glucose (KRG) solution were prepared. SCH79797 was purchased from Tocris (Bristol, UK), DNA-aptamers HD1 and HD22 were from Biomers.net (Ulm, Germany). A cocktail of protease inhibitors was purchased from Thermo Fisher (Waltham, MA, US).
Cloning, directed mutagenesis, transformation, and expression of PAR4 in

Saccharomyces cerevisiae
PAR4 cDNA was kindly provided by Dr Kuliopulos (Tufts University, Boston, MA US) and inserted into the plasmid pcDEF3 by the restriction sites EcoRI at mi' 5' end and XbaI at 3' end, using E. coli strain DH10B for subcloning and plasmid propagation platform. The destination plasmid (Supplemental Table 1 ) for yeast expression of pG426 was kindly provided by Dr Simon Dowell (GSK, Stevenage, UK). The cloning strategy was performed by inserting PAR4 restricted fragment of pCDEF3 upstream and downstream of the PAR4 cDNA in an open reading frame and saving their Kozak sequences of the cDNA using the restriction sites 5minSpeI and 3minSmaI. Ligation (see plasmids used in Supplemental Table 2 ) was confirmed by restriction and sequencing. BMH 71-18 mutS E. coli strain from was used to perform directed mutagenesis provided its defective mutation to repair DNA mismatches while DH10B E. coli strain was used for ligation experiments and plasmid propagation. The resulting p426GPD-PAR4 plasmid was used as a platform for PAR4 directed mutagenesis using the Transformer kit from Clontech (Mountain View, CA, US) following the manufacturer's instructions, see Supplementary Table 2 for strain used. Primers used for this purpose are listed in Supplemental Table 2 . Both mutated and native PAR4 cDNAs were transformed in yeast strain MMY12 (also kindly donated by Dr Simon Dowell).
The method to transform yeast was a modification of the Geitz method [19] , as described by Dowell and Brown [20] . Positive clones for transformation were selected by auxotrophic growth on minimal -Uracil media. x2)) dilution factor is due to the use of 0.25mL of sample lysate on 0.5 mL of reagent.
The formula and method was based on the method described by Dowell and Brown [20] .
Blood collection and platelet preparation
Blood was collected from healthy donors after informed consent and approval from the local ethics committee. From heparinized containers (10 IU/mL) the blood was transferred to 50 mL Falcon tubes and mixed with anticoagulant citrate dextrose (ACD) solution 5:1 (v:v) (71 mM citric acid, 85 mM sodium citrate and 111 mM glucose) and centrifuged at 220 x g for 20 min to obtain platelet-rich plasma which was then incubated with 0.5 U/mL apyrase, followed by centrifugation at 520 x g for 20 min to collect the platelets. The platelet solution was carefully washed three times by exchanging supernatant with Krebs-Ringer glucose (KRG) buffer (120 mM NaCl, 4.9 mM KCl, 1.2 mM MgSO4, 1.7 mM KH2PO4, 8.3 mM Na2HPO4 and 10 mM glucose, pH 7.3) and finally re-suspended in KRG containing 1 U/mL apyrase. The platelet count was measured using a blood cell counter (ABX Diagnostics Micros 60, Ramsey, MN, USA or Swelab Alfa Basic Cell Counter, Swelab, Spånga, Sweden) and adjusted to 2.5×10 8 platelets/mL. Suspensions were supplemented with 1 mM CaCl2 before use.
For cleavage assays, α or γ-thrombin were added at the final working concentration (see each setting in results) in the platelet suspension, with or without other additions, as stated in figure legends. After incubation at RT for 20, the samples were immediately frozen using dry ice. After brief thawing at 37°C of samples, they were treated for Western Blot as described below. of the platelets and the other containing the brightest 0.5-1.5% of the platelets. Platelets with fluorescence intensity higher than this cut-off were identified as fibrinogen binding or P-selectin positive cells, respectively. Control samples without thrombin were run for each donor to ensure that the platelets were not pre-activated. All samples were tested in duplicates.
SDS-PAGE gel electrophoresis and Western Blotting
Western blotting of platelet proteins was performed essentially as described before [17] .
Samples were incubated in KRG buffer with/without agonist and thereafter mixed with 80-100 µL of lysis buffer (Tris-HCl 50 mM pH 7.5 + 2% Tween + protease inhibitor cocktail (Thermo Fisher, Waltham, MA, USA). After a brief vortex, samples were frozen at -70°C for 15 min and exposed to three thawing cycles in total. This was followed by a short centrifugation to pellet debris after which the supernatant was collected and the protein concentration measured using the micro-BCA method Binding was detected by reaction with a commercial ECL reagent (Immobilon™, Millipore, Merck, Darmstadt, Germany), photographic film exposure was performed in a photographic dark chamber FUJI LAS-1000 under the control of Image Reader software V2.6 (Minato, Tokyo Japan).
Light transmission aggregometry
Aliquots (0.5 mL) of platelet suspension (approximately at 2,500 platelets/µL) were preincubated at 37°C for 2 min. The blank was set with dilution buffer for platelets (KRGbuffer) at the same time for all channels. Platelet suspensions were added and initially run for 3-4 min to check for spontaneous aggregation, if this occurred, the preparation was discarded. Thereafter, platelet aggregation was induced by adding thrombin or ADP in the presence or absence of the PAR4-mimicking peptides. Changes in light absorbance were recorded using a Chronolog Dual Channel lumi-aggregometer (Model 560, Chrono-Log, Haverston, PA, US).
Enzymatic activity of thrombin
The enzymatic activity of thrombin was recorded by use of a fluorogenic substrate ZGly-Gly-Arg-AMC, final concentration 0.4 mM. α-thrombin at 14 nM or γ-thrombin at 20 nM was incubated in presence or absence of the PAR4 peptides, final concentration 600 µM and the fluorescence measurements were recorded for 20 min.
Tryptophan fluorescence studies of PAR4 peptides binding to γ-thrombin.
Binding of PAR4 peptides to γ-thrombin was studied by monitoring the decrease in tryptophan fluorescence intensity of thrombin at its λmax (341 nm) as a function of PAR4 peptide concentration. Fluorescence intensity measurements were performed on 1 μM thrombin in PBS by exciting at 295 nm and collecting emission spectra between 310 -500 nm using a slit width of 5 nm. All fluorescence measurements were performed at 22°C using a Horiba JobinYvon (Kyoto, Japan) Fluoromax-4 spectrofluorimeter fitted with a Peltier model temperature control system.
Stock solutions of PAR4 peptides (12-20 mM) were prepared by dissolving peptides initially in DMSO and subsequently diluting with PBS to a final DMSO concentration of 5%. Small aliquots (0.5 -5 μL) of these stock peptide solutions were titrated into a cuvette containing 400 μL of 1 μM thrombin in PBS. Total peptide solution added did not exceed 7% of final volume. The samples were mixed thoroughly after each peptide addition and before fluorescence measurement. Control experiments to check for nonspecific peptide binding to thrombin was performed, in which thrombin was titrated with a PAR4 peptide control peptide pseudo 223-239 whose amino acid sequence was scrambled. All spectra were corrected to remove background signal from buffer. Peptide concentrations were determined using Micro-BCA assay (Thermo Fischer), and the concentration of thrombin was determined using its absorbance at 280 nm and an extinction co-efficient (1%) of 18.3. 
Results
Mutation of aspartic acid residues in PAR4 reveal a role for ECLII in receptor activation by thrombin
We chose the yeast (Saccharomyces cerevisiae) strain MMY12 as the system to express PAR4 and its mutants since this strain was previously used in the expression of many human GPCRs [20] , including human PAR1 [21] . Based on previous studies, it appears that the anionic residues of PAR4 play an important role in its interaction with thrombin [16] . Hence, we generated three different mutants of PAR4 where the aspartic residues within the ECLII region were mutated either at a single residue or at multiple residues.
In addition, as controls, we generated two single mutants, one at the N-terminal of ECLII and the other in the ECLIII region (Table 1) previously been shown to block the thrombin exosites I and II, respectively [11] . When we compared the activity of wtPAR4 with those of its mutants, we observed that all PAR4 ECLII mutants showed a significant decrease in their activity ( Figure 1 ). Of these, the double and triple mutants showed the most significant decrease, suggesting an additive effect. Furthermore, the response to the PAR4 activating peptide, PAR4-AP was abolished. The PAR4 N-terminal mutant (D57A+D59A) also showed a significant decrease in activity for thrombin, which is in accordance to what is previously known about the contribution of aspartic residues and the key role of the N-terminal in PAR4
activation. The activity of the mutant D309A whose mutation lies in the ECLIII region, was similar to that of wtPAR4, indicating that the aspartic acid residues in this region are not as important to the activity, as are those in the ECLII region. In addition, the results for the PAR4-AP indicate a binding of the new N-terminal of PAR4, created by cleavage by thrombin, to ECLII.
Since PAR receptors are activated upon the cleavage of its N-terminal by thrombin, we wanted to check if the decrease in activity observed for the PAR4 mutants was due to α-thrombin's inability to cleave them. Western Blot analysis using an antibody specific for the non-cleaved PAR4 N-terminal showed that the cleavage of double and triple mutants by α-thrombin was attenuated (Figure 2 ). These results suggest that PAR4
cleavage is facilitated by interactions between α-thrombin and the aspartic residues in ECLII.
Peptides mimicking PAR4 ECLII and N-terminal affect responses to thrombin in human platelets
After confirming the importance of the aspartic residues 224, 230 and 235 at ECLII of human PAR4 in a eukaryotic model, we investigated the importance of these residues in the activation of human platelets. To do this, we employed three short peptides (13) (14) (15) (16) (17) aa in length) representing regions of PAR4 containing the key aspartic acids identified in the mutation experiments. While one of the peptide sequences represented the Nterminal region, the other two represented the ECLII region. The peptide sequences were selected keeping in mind their stability (calculated index in solution, sequences are listed in Table 2 ). The potential of the peptides to affect thrombin activation of human platelets was assessed by flow cytometry. Platelet activation was measured as expressed P-selectin ( Figure 3A-B) or the active state of fibrinogen receptor GPIIb/IIIa using the specific monoclonal antibody PAC-1 ( Figure 3C-D) . A dose-dependent inhibition was observed when γ-thrombin was used to activate platelets ( Figure 3A, 3C ). Table 2 , with similar properties to the ECLII peptides, considering number of amino acids, molecular weight and pI, but lacking the electronegative amino acids proposed to be causing the observed effects) at the same working concentration. The P-selectin expression in response to 20 nM γ-thrombin was 69.3 ± 12.3% in the absence and 65.7 ± 18.5 % in the presence of 600 µM of this scrambled peptide (mean ±SD, n=4). This, together with the lack of any significant difference in platelet activation in the presence of this peptide ( Figure 3A , 3C and 4) leads us to conclude that the observed effects with the ECLII peptides are due to their specific amino acid sequence.
We further investigated whether these results were caused by a decreased N-terminal cleavage of PAR4, by using the same N-terminal-specific antibody as in the yeast model. Indeed, the decrease in the PAR4 band upon thrombin activation was less pronounced in the presence of the peptides (supplemental Figure S -5) . The N-terminal and thus also the 55-67 peptide is expected to bind to exosite I, thus affecting cleavage by both α-thrombin and γ-thrombin. The 223-239 peptide is affecting cleavage less by α-thrombin than by γ-thrombin since the latter lacks exosite I, making the exosite II more important for binding to PAR4 and more easily occupied by the 223-239 peptide.
However, cross-interactions are unavoidable due to the electrostatic similarities of the peptides.
Specificity for PAR4
To check that the peptides were specifically affecting thrombin-induced PAR4 activation, we confirmed that they did not affect platelet activation by ADP in flow cytometry (supplementary Figure S-6 
Discussion
The activation of PAR1 by thrombin has been studied in detail, including structural information obtained from crystallography [14] . These studies could confirm previous reports stating that ECLII is the binding site for the new N-terminal formed after cleavage by thrombin [15] . Based on the sequence homology between PAR4 and PAR1, and the conserved pair of cysteines in the ECLII allowing a key disulphide bridge, it could be expected that the ECLII played a role for PAR4 activation as well. If present, this interaction would add to the well-known function of the N-terminal for thrombin binding and receptor activation.
We recently reported that exosite II in thrombin was critical for activation of PAR4
and that this interaction was unaffected by blockage of the previously known interaction between thrombin and GpIbα [17] . These findings are supported by a previous study where introduction of the mutation W215A in thrombin exosite II reduced PAR4 cleavage 280-fold and increased Kd 800-fold for PAR4 but no changes at all for PAR1 [18] . The mutated tryptophan in thrombin could be involved in the stability of the structure of exosite II as it is a key amino acid in several hydrogen bridges [6] . In addition, it may also be involved in hydrophobic interactions, which might be of relevance for the interaction with PAR4.
PAR4 contains a cluster of electronegative residues in the ECLII, with aspartic residues in positions 224, 230 and 235, and another cluster at positions 57, 59 and 66 in the Nterminal. The interaction between a peptide from the PAR4 N-terminal with exosite I in thrombin has been described [22] , this is another evidence that lead us to believe that we could expect to find similar effects in the interaction with exosite II, due to the electrostatic similarities between exosite I and II [23] , and the confirmed importance of anionic residues for the interaction with exosites [16] . Although the data from Bah et al [22] depicts and demonstrates a clear interaction only with exosite I, an alternative interaction with exosite II cannot be discarded, as their study was exclusively made with peptides mimicking N-terminal areas and was focused on the interaction with exosite I.
We suspected that electronegative amino acids in ECLII of PAR4 could be important for its interaction with thrombin, in analogy with the ECLII in PAR1 [16] . To test this hypothesis, we induced the expression of human wtPAR4 and several mutants of interest in a yeast model. Indeed, we found that the activation of PAR4 by thrombin was abolished in the triple ECLII mutant (D224A, D230A, D235A) and attenuated in the single D224A and the double mutant (D230A, D235A) but not attenuated in the single ECLIII mutant, D309A. When ƴ-thrombin (a proteolytic product of α-thrombin, which lacks exosite I) was used as activator, the effects of the ECLII mutations were more pronounced than when using α-thrombin, which speaks in favour of an interaction between exosite II and ECLII. In accordance with previous studies [22] , mutations in the N-terminal attenuated the response to both types of thrombin. Furthermore, the response to PAR4-AP was also abolished in the triple mutant and attenuated much like thrombin in the other mutations, with the important exception of mutations in the Nterminal of PAR4. This suggests ECLII as the binding site for the new N-terminal formed after thrombin cleavage.
To test our findings in the more physiological context of platelet activation, we used peptides mimicking the parts with electronegative clusters in the N-terminal and in ECLII to study potential inhibiting effects on thrombin activation of human platelets.
None of the peptides had much effect on platelet activation by α-thrombin, measured as fibrinogen receptor activation or P-selectin expression utilizing flow cytometry, but the response to ƴ-thrombin was attenuated (Figure 3) . A possible explanation is that in The results indicate a relatively weak binding, but as the apparent Kd values were determined indirectly, these results are only useful as an indicator of peptide affinity and specificity to thrombin, and therefore they might not fully reflect their potential effects in the platelet experiments. Human γ-thrombin contains 9 tryptophan residues and due to the existence of multiple tryptophan residues on γ-thrombin, it is difficult to ascertain which residues are directly affected by peptide binding or the exact binding location of the peptides to thrombin.
The large impact seen for PAR4 mutants in the yeast model must be interpreted with caution, as yeast cells are lacking other GPCR pathways that would potentially modulate the extent of responses in other cells such as platelets. In addition, the role for these domains in the formation of receptor homo-and heterodimers (with PAR1) has not been investigated, but might be a future area of investigation in this field.
In conclusion, our results support a role for the aspartic residues of ECLII in thrombin binding and activation of PAR4 and suggest that the docking site for the new Nterminus unmasked by thrombin cleavage is situated in ECLII. Our results also suggest that ECLII is involved in direct interaction with thrombin, with exosite II as the probable counterpart, in analogy to the previously described mechanism for thrombin interaction with PAR1. 
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